VCs Back ObsEva With $35M For Trials On Pre-term Labor Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss start-up will conduct a Phase II study on a compound that may reduce or prevent pre-term labor contractions, licensed from Merck Serono. It hopes to follow in the footsteps of another women's health company, PregLem, which provided exceptional returns with the same CEO and similar investors.
You may also be interested in...
Start-Up Quarterly Statistics, Q3 2013
Start-up fundraising for Q3 2013 totaled $559.4 million, down from last quarter’s big rally ($907.2 million) but still up from the sluggish first quarter ($398.7 million). More than half of that money went to biopharma companies, a group which also received investments through alliances with equity provisions.
Financings Of The Fortnight: VCs Not Wowed By Single-Asset Company Model
Venture capitalists tell START-UP’s annual survey that seeing will be believing when it comes to the potential of single-asset models. Plus news on recent financings by iPierian, Evotec, ObsEva and Acacia.
Close To Filing Esmya, PregLem Licenses Candidate For Post-Operative Adhesions
The Swiss women's reproductive health-focused firm plans to move new program into Phase II in 2011.